RecruitingPhase 4NCT07272343

The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes

A Study on the Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes Combined With Metabolic-associated Fatty Liver Disease and Its Molecular Mechanisms

Sponsor

Second Affiliated Hospital of Nanchang University

Enrollment

100 participants

Start Date

Feb 10, 2023

Study Type

INTERVENTIONAL

Conditions

Type 2 Diabetes Mellitus (T2DM)Semaglutide Caloric Restriction

Summary

To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory markers, liver fat content, and other parameters. The study also observed the subcutaneous and visceral fat of the participants and explored the molecular mechanisms of action, providing high-quality evidence-based support for the timing and targets of intervention in this population.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing semaglutide (a GLP-1 weight-loss and diabetes drug) to calorie restriction alone in people who were recently diagnosed with type 2 diabetes, to see which approach is more effective at improving blood sugar and metabolic health. **You may be eligible if...** - You are between 18 and 75 years old - You have a BMI of 25 or higher - You were diagnosed with type 2 diabetes within the past 3 months - Your HbA1c (a blood sugar average) is 8.5% or lower - You have not yet started any diabetes medications **You may NOT be eligible if...** - You have had diabetes for more than 3 months or are already on medication for it - You have type 1 diabetes or another form of diabetes - You have significant heart, kidney, or liver disease - You are pregnant or breastfeeding - You have a personal or family history of medullary thyroid cancer Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGsemaglutide

The semaglutide group received weekly subcutaneous semaglutide (0.25 mg for weeks 1-2, 0.5 mg for weeks 3-4, and 1.0 mg for weeks 5-12).

BEHAVIORALcaloric restriction

The caloric restriction group followed a gender-specific daily caloric restriction (1,500-1,800 kcal for males; 1,200-1,500 kcal for females).

Locations(1)

Minde road No.1

Jiangxi, Nanchang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07272343

Related Trials

Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 Diabetes

NCT066138541 location

Optimization and Evaluation of the Diagnosis and Treatment System for Diabetic Retinopathy in Type 2 Diabetes Mellitus

NCT068213993 locations

A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM

NCT0684520220 locations

A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus

NCT074652241 location

Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass

NCT072728371 location